November 25, 2019
High G0 Glycosylation Level Driving Program Acceleration
November 13, 2019
JUPITER, FL / ACCESSWIRE / November 13, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of bi...
October 30, 2019
JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performan...
October 28, 2019
JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 tec...
October 10, 2019
JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance...
September 4, 2019
JUPITER, FL / ACCESSWIRE / September 4, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performanc...
August 21, 2019
JUPITER, FL / ACCESSWIRE / August 21, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance ...
August 13, 2019
JUPITER, FL / ACCESSWIRE / August 13, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of...
July 30, 2019
JUPITER, FL / ACCESSWIRE / July 30, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the perform...
July 5, 2019
JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022 with VTT Technical Research Centre ...